CSF complement 3 and factor H are staging biomarkers in Alzheimer's disease

Alzheimer’s Disease Neuro-Imaging Initiative

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

INTRODUCTION: CSF levels of established Alzheimer's disease (AD) biomarkers remain stable despite disease progression, and non-amyloid non-tau biomarkers have the potential of informing disease stage and progression. We previously identified complement 3 (C3) to be decreased in AD dementia, but this change was not found by others in earlier AD stages. We hypothesized that levels of C3 and associated factor H (FH) can potentially distinguish between mild cognitive impairment (MCI) and dementia stages of AD, but we also found their levels to be influenced by age and disease status.

RESULTS: We developed a biochemical/bioinformatics pipeline to optimize the handling of complex interactions between variables in validating biochemical markers of disease. We used data from the Alzheimer's Disease Neuro-imaging Initiative (ADNI, n = 230) to build parallel machine learning models, and objectively tested the models in a test cohort (n = 73) of MCI and mild AD patients independently recruited from Emory University. Whereas models incorporating age, gender, APOE ε4 status, and CSF amyloid and tau levels failed to reliably distinguish between MCI and mild AD in ADNI, introduction of CSF C3 and FH levels reproducibly improved the distinction between the two AD stages in ADNI (p < 0.05) and the Emory cohort (p = 0.014). Within each AD stage, the final model also distinguished between fast vs. slower decliners (p < 0.001 for MCI, p = 0.007 for mild AD), with lower C3 and FH levels associated with more advanced disease and faster progression.

CONCLUSIONS: We propose that CSF C3 and FH alterations may reflect stage-associated biomarker changes in AD, and can complement clinician diagnosis in diagnosing and staging AD using the publically available ADNI database as reference.

Original languageEnglish (US)
Number of pages1
JournalActa neuropathologica communications
Volume4
DOIs
StatePublished - Feb 17 2016

Fingerprint

Complement Factor H
Complement C3
Alzheimer Disease
Biomarkers
Disease Progression
Computational Biology
Amyloid
Dementia

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

CSF complement 3 and factor H are staging biomarkers in Alzheimer's disease. / Alzheimer’s Disease Neuro-Imaging Initiative.

In: Acta neuropathologica communications, Vol. 4, 17.02.2016.

Research output: Contribution to journalArticle

@article{2d167af1e2fd4354b6d373f6ee039c84,
title = "CSF complement 3 and factor H are staging biomarkers in Alzheimer's disease",
abstract = "INTRODUCTION: CSF levels of established Alzheimer's disease (AD) biomarkers remain stable despite disease progression, and non-amyloid non-tau biomarkers have the potential of informing disease stage and progression. We previously identified complement 3 (C3) to be decreased in AD dementia, but this change was not found by others in earlier AD stages. We hypothesized that levels of C3 and associated factor H (FH) can potentially distinguish between mild cognitive impairment (MCI) and dementia stages of AD, but we also found their levels to be influenced by age and disease status.RESULTS: We developed a biochemical/bioinformatics pipeline to optimize the handling of complex interactions between variables in validating biochemical markers of disease. We used data from the Alzheimer's Disease Neuro-imaging Initiative (ADNI, n = 230) to build parallel machine learning models, and objectively tested the models in a test cohort (n = 73) of MCI and mild AD patients independently recruited from Emory University. Whereas models incorporating age, gender, APOE ε4 status, and CSF amyloid and tau levels failed to reliably distinguish between MCI and mild AD in ADNI, introduction of CSF C3 and FH levels reproducibly improved the distinction between the two AD stages in ADNI (p < 0.05) and the Emory cohort (p = 0.014). Within each AD stage, the final model also distinguished between fast vs. slower decliners (p < 0.001 for MCI, p = 0.007 for mild AD), with lower C3 and FH levels associated with more advanced disease and faster progression.CONCLUSIONS: We propose that CSF C3 and FH alterations may reflect stage-associated biomarker changes in AD, and can complement clinician diagnosis in diagnosing and staging AD using the publically available ADNI database as reference.",
author = "{Alzheimer’s Disease Neuro-Imaging Initiative} and Hu, {William T.} and Watts, {Kelly D.} and Prashant Tailor and Nguyen, {Trung P.} and Howell, {Jennifer C.} and Lee, {Raven C.} and Seyfried, {Nicholas T.} and Marla Gearing and Hales, {Chadwick M.} and Levey, {Allan I.} and Lah, {James J.} and Lee, {Eva K.}",
year = "2016",
month = "2",
day = "17",
doi = "10.1186/s40478-016-0277-8",
language = "English (US)",
volume = "4",
journal = "Acta neuropathologica communications",
issn = "2051-5960",
publisher = "BioMed Central",

}

TY - JOUR

T1 - CSF complement 3 and factor H are staging biomarkers in Alzheimer's disease

AU - Alzheimer’s Disease Neuro-Imaging Initiative

AU - Hu, William T.

AU - Watts, Kelly D.

AU - Tailor, Prashant

AU - Nguyen, Trung P.

AU - Howell, Jennifer C.

AU - Lee, Raven C.

AU - Seyfried, Nicholas T.

AU - Gearing, Marla

AU - Hales, Chadwick M.

AU - Levey, Allan I.

AU - Lah, James J.

AU - Lee, Eva K.

PY - 2016/2/17

Y1 - 2016/2/17

N2 - INTRODUCTION: CSF levels of established Alzheimer's disease (AD) biomarkers remain stable despite disease progression, and non-amyloid non-tau biomarkers have the potential of informing disease stage and progression. We previously identified complement 3 (C3) to be decreased in AD dementia, but this change was not found by others in earlier AD stages. We hypothesized that levels of C3 and associated factor H (FH) can potentially distinguish between mild cognitive impairment (MCI) and dementia stages of AD, but we also found their levels to be influenced by age and disease status.RESULTS: We developed a biochemical/bioinformatics pipeline to optimize the handling of complex interactions between variables in validating biochemical markers of disease. We used data from the Alzheimer's Disease Neuro-imaging Initiative (ADNI, n = 230) to build parallel machine learning models, and objectively tested the models in a test cohort (n = 73) of MCI and mild AD patients independently recruited from Emory University. Whereas models incorporating age, gender, APOE ε4 status, and CSF amyloid and tau levels failed to reliably distinguish between MCI and mild AD in ADNI, introduction of CSF C3 and FH levels reproducibly improved the distinction between the two AD stages in ADNI (p < 0.05) and the Emory cohort (p = 0.014). Within each AD stage, the final model also distinguished between fast vs. slower decliners (p < 0.001 for MCI, p = 0.007 for mild AD), with lower C3 and FH levels associated with more advanced disease and faster progression.CONCLUSIONS: We propose that CSF C3 and FH alterations may reflect stage-associated biomarker changes in AD, and can complement clinician diagnosis in diagnosing and staging AD using the publically available ADNI database as reference.

AB - INTRODUCTION: CSF levels of established Alzheimer's disease (AD) biomarkers remain stable despite disease progression, and non-amyloid non-tau biomarkers have the potential of informing disease stage and progression. We previously identified complement 3 (C3) to be decreased in AD dementia, but this change was not found by others in earlier AD stages. We hypothesized that levels of C3 and associated factor H (FH) can potentially distinguish between mild cognitive impairment (MCI) and dementia stages of AD, but we also found their levels to be influenced by age and disease status.RESULTS: We developed a biochemical/bioinformatics pipeline to optimize the handling of complex interactions between variables in validating biochemical markers of disease. We used data from the Alzheimer's Disease Neuro-imaging Initiative (ADNI, n = 230) to build parallel machine learning models, and objectively tested the models in a test cohort (n = 73) of MCI and mild AD patients independently recruited from Emory University. Whereas models incorporating age, gender, APOE ε4 status, and CSF amyloid and tau levels failed to reliably distinguish between MCI and mild AD in ADNI, introduction of CSF C3 and FH levels reproducibly improved the distinction between the two AD stages in ADNI (p < 0.05) and the Emory cohort (p = 0.014). Within each AD stage, the final model also distinguished between fast vs. slower decliners (p < 0.001 for MCI, p = 0.007 for mild AD), with lower C3 and FH levels associated with more advanced disease and faster progression.CONCLUSIONS: We propose that CSF C3 and FH alterations may reflect stage-associated biomarker changes in AD, and can complement clinician diagnosis in diagnosing and staging AD using the publically available ADNI database as reference.

UR - http://www.scopus.com/inward/record.url?scp=85012159785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012159785&partnerID=8YFLogxK

U2 - 10.1186/s40478-016-0277-8

DO - 10.1186/s40478-016-0277-8

M3 - Article

C2 - 26887322

AN - SCOPUS:85012159785

VL - 4

JO - Acta neuropathologica communications

JF - Acta neuropathologica communications

SN - 2051-5960

ER -